Delivering the next generation of gene therapies

Our mission

Gene Therapy based on Adeno-Associated Viral (AAV) vectors has proven to be transformative in the treatment of genetic illnesses, however, the small vector payload limits their further application.

The AAVantgarde cutting-edge gene therapy technology platforms are focused on solving the constraint of oversized gene delivery, with our technologies opening up the opportunity for genetic medicine delivery to more underserved patients with debilitating diseases.

About us

Delivering the next generation of gene therapies

Focused on broadening the application of AAV-based gene therapies.

Pipeline

Advancing our platforms

AAVantgarde has two proprietary, AAV-based large gene delivery platforms.

AAV gene therapy has been limited by transgene capacity, and AAVantgarde’s proprietary platforms enable delivery of large genes to tissue and cells in vivo; something that could extend into many disease areas”

Prof. Alberto Auricchio Founder, AAVANTGARDE